儿童脑髓母细胞瘤的分子亚型,预后因素和治疗优化:来自中国的现实研究
Jingjing Liu1, Yanling Sun1, Huming Li2
1Department of Pediatrics, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Frontiers in oncology
|August 14, 2025
概括
这项研究确定了中国儿童中脑髓母细胞瘤 (MB) 再发和死亡率的关键风险因素. 研究结果强调TP53突变和MYCN放大是个性化治疗策略的关键指标.
科学领域:
- 儿科瘤学 儿科瘤学
- 神经瘤学神经瘤学
- 分子诊断学 分子诊断
背景情况:
- 脑髓母细胞瘤 (MB) 是最常见的恶性儿科脑瘤.
- 对中国儿科MB的分子特征和治疗疗效的系统研究很少.
- 这项研究调查了复发和死亡风险因素以及强化化疗的可行性.
研究的目的:
- 评估中国儿科脑髓母细胞瘤患者中复发和死亡的临床和分子风险因素.
- 评估TP53突变和MYCN放大等遗传变化的预后相关性.
- 为风险适应和个性化治疗策略提供信息.
主要方法:
- 对381名儿科脑髓母细胞瘤患者的回顾性分析.
- 卡普兰-梅尔对生存率的分析.
- 考克斯回归以确定复发和死亡率的独立风险因素.
主要成果:
- 5年无进展生存率 (PFS) 为69.9%,整体生存率 (OS) 为80.6%.
- WNT-MB显示出最好的预后;3-MB组出现了最糟糕的情况.
- 独立的复发风险因素包括高风险状态,TP53突变,MYCN放大,染色体12p放大和9q删除. 死亡率与LC/A病理,TP53突变和高风险状态有关.
结论:
- 确定了儿科骨髓母细胞瘤复发和死亡率的关键临床和分子风险因素.
- TP53突变,MYCN放大和染色体变化是显著的预后指标.
- 这些发现支持针对脑髓母细胞瘤的风险调整和个性化治疗策略.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


